Evidence map›Paper›PMID 28299326›Full record

ArticleBioMed research international2017

Production of Human Cu,Zn SOD with Higher Activity and Lower Toxicity in

Kun Zhang, Yuejuan Zhang, Jing Zi, Xiaochang Xue, Yi Wan

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kun ZhangMicrobiology Institute of Shaanxi, Xi'an 710043, China.ORCID 0000-0002-1448-1373
Yuejuan ZhangMicrobiology Institute of Shaanxi, Xi'an 710043, China.ORCID 0000-0001-8120-2031
Jing ZiMicrobiology Institute of Shaanxi, Xi'an 710043, China.ORCID 0000-0001-5984-6834
Xiaochang XueState Key Laboratory of Cancer Biology, Department of Biopharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China.ORCID 0000-0001-9718-4659
Yi WanMicrobiology Institute of Shaanxi, Xi'an 710043, China.ORCID 0000-0002-0275-9374
Microbiology Institute of Shaanxi · CNAir Force Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although, as an antioxidant enzyme, human Cu,Zn superoxide dismutase 1 (hSOD1) can mitigate damage to cell components caused by free radicals generated by aerobic metabolism, large-scale manufacturing and clinical use of hSOD1 are still limited by the challenge of rapid and inexpensive production of high-quality eukaryotic hSOD1 in recombinant forms. We have demonstrated previously that it is a promising strategy to increase the expression levels of soluble hSOD1 so as to increase hSOD1 yields in

Indexed as

MutationAnimalsCell LineCricetinaeCysteineDisulfidesDNA DamageEscherichia coliHumansMelanocytesMelanoma, ExperimentalOxidation-ReductionRecombinant ProteinsSuperoxide Dismutase-1CysteineDisulfidesRecombinant ProteinsSuperoxide Dismutase-1

Identifiers

PMID28299326
PMCPMC5337334
OpenAlexW2587874375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.